Literature DB >> 19230158

Correlates of protection: novel generations of influenza vaccines.

Guus F Rimmelzwaan1, Janet E McElhaney.   

Abstract

The emergence of avian influenza A/H5N1 viruses that can cross the species barrier and that cause often-fatal infections of humans is of great concern and a pandemic outbreak with these viruses is feared. The availability of effective vaccines that can protect against morbidity and mortality caused by these viruses is highly desirable and great efforts are being made to prepare these vaccines. The circulation of variants of antigenically distinct influenza H5N1 viruses belonging to different clades complicates the development of new vaccines. Preferably, vaccines induce broad protective immunity against intra-subtypic variants and ideally, also hetero-subtypic immunity. A good understanding of the correlates of immune protection may aid in the development of such vaccines. Here we reviewed potential correlates of protection against influenza and discussed some of the vaccination strategies that could result in optimal protection against epidemic and pandemic influenza.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19230158     DOI: 10.1016/j.vaccine.2008.07.043

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

3.  Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population.

Authors:  Chia-Yu Chi; Ching-Chuan Liu; Chia-Chun Lin; Hsuan-Chen Wang; Yung-Tsung Cheng; Chung-Ming Chang; Jen-Ren Wang
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

4.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

5.  Population viscosity suppresses disease emergence by preserving local herd immunity.

Authors:  Timothy C Reluga; Eunha Shim
Journal:  Proc Biol Sci       Date:  2014-12-07       Impact factor: 5.349

Review 6.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.

Authors:  Balaji Manicassamy; Rafael A Medina; Rong Hai; Tshidi Tsibane; Silke Stertz; Estanislao Nistal-Villán; Peter Palese; Christopher F Basler; Adolfo García-Sastre
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

8.  Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Authors:  Michael Schotsaert; Lorena Itatí Ibañez; Walter Fiers; Xavier Saelens
Journal:  J Biomed Biotechnol       Date:  2010-05-24

Review 9.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

10.  B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant.

Authors:  Jane Baer; Felix Santiago; Hongmei Yang; Hulin Wu; Jeanne Holden-Wiltse; John Treanor; David J Topham
Journal:  Vaccine       Date:  2009-11-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.